SLUG: daewoong-pharmaceutical-069620-q1-2026-operating-profit-collapses-capex-surge
META: Daewoong Pharma Q1 2026: Revenue hits ₩377.8B (+6% YoY) but operating profit crashes 42.6% to ₩22.2B; net income misleads at +29% on one-time gain.
Source: Q1 2026 Quarterly Report (분기보고서) — Filed Q2 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Daewoong Pharmaceutical (069620.KS) Q1 2026: Revenue +6% but Operating Profit Collapses 42.6% as CapEx Surge Drains Cash”
This article became available on July 21, 2026. Subscribe to read in full, or wait until October 19, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.
You just read what happened. Here's how to read what it means.
LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.
We read Daewoong Pharmaceutical's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the Daewoong Pharmaceutical reportReading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.
